IgG1 monoclonal antibody against CD38; mediates ADCC, CDC, and ADCP, can induce direct apoptosis, and reduces CD38+ immunosuppressive cells to augment T/NK-cell function.
Humanized IgG1 monoclonal antibody against CD38 that binds CD38 on tumor cells and induces ADCC, CDC, and ADCP, can trigger direct apoptosis, and depletes CD38+ immunosuppressive cells to enhance T/NK-cell function.
YES
DIRECT
Isatuximab binds CD38 on target cells and induces NK cell–mediated ADCC, complement-dependent cytotoxicity (CDC), macrophage ADCP, and can trigger direct apoptosis.
Bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks ligand-mediated activation, inhibits downstream MAPK/PI3K-AKT/JAK-STAT signaling, promotes receptor internalization/degradation, and engages immune effector cells via Fc to mediate ADCC.
Bispecific IgG1 monoclonal antibody against EGFR and MET that blocks ligand-mediated receptor activation and phosphorylation, suppressing downstream MAPK, PI3K/AKT, and JAK/STAT signaling; induces receptor internalization/degradation and engages Fc-dependent immune effector functions to mediate ADCC.
YES
DIRECT
Amivantamab binds EGFR on target cells and engages Fcγ receptor–bearing immune cells to mediate ADCC (and ADCP/CDC), resulting in killing of EGFR-expressing cells; it also promotes receptor internalization and signaling blockade.
Bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks ligand-mediated activation, inhibits downstream MAPK/PI3K-AKT/JAK-STAT signaling, promotes receptor internalization/degradation, and engages immune effector cells via Fc to mediate ADCC.
Bispecific IgG1 monoclonal antibody against EGFR and MET that blocks ligand-mediated receptor activation and phosphorylation, suppressing downstream MAPK, PI3K/AKT, and JAK/STAT signaling; induces receptor internalization/degradation and engages Fc-dependent immune effector functions to mediate ADCC.
YES
DIRECT
Amivantamab binds MET on target cells and, via its IgG1 Fc, recruits Fc receptor–bearing immune effectors (e.g., NK cells) to mediate ADCC, killing MET-expressing cells.
Anti-CD20 chimeric monoclonal antibody; depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20-positive cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.
YES
DIRECT
Anti-CD20 antibody binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP; it can also induce apoptosis of CD20+ cells.
Anti-CD79b antibody–drug conjugate delivering MMAE; internalization releases a microtubule inhibitor causing G2/M arrest and apoptosis.
Anti-CD79b monoclonal antibody linked via a protease-cleavable linker to the microtubule inhibitor MMAE; binding to CD79b on B cells triggers internalization and intracellular release of MMAE, which inhibits tubulin polymerization, leading to G2/M arrest and apoptosis of malignant B cells.
YES
DIRECT
ADC binds CD79b on B cells, is internalized, linker is cleaved to release MMAE, which inhibits tubulin polymerization causing G2/M arrest and apoptosis of the target-expressing cells.